Centrum Medyczne Intercor Sp. z o.o.

At Centrum Medyczne Intercor researchers are evaluating innovative treatments for heart failure, atherosclerotic disease, hypertension, and related vascular conditions. The studies aim to reduce cardiovascular events and improve cardiac function.

• Heart failure
• Atherosclerotic cardiovascular disease
• Hypertension
• Peripheral arterial disease
• Mixed dyslipidemia
• Elevated lipoprotein(a)

The site currently hosts 30 active trials with 23 investigators, highlighting a strong focus on cardiovascular research in Bydgoszcz, Poland.

Clinical programs at the center target liver health, testing new agents for non‑alcoholic steatohepatitis and alcohol‑related liver injury. The goal is to slow disease progression and improve liver function.

• Non‑alcoholic steatohepatitis (NASH)
• Alcohol‑related liver disease
• Metabolic liver disorders

With a portfolio of 30 trials, the institute leverages its multidisciplinary team to advance digestive disease therapeutics.

The department conducts studies on endocrine disorders such as acromegaly, Graves’ disease, and diabetes. Trials assess novel hormone‑modulating drugs and combination regimens to improve metabolic control.

• Acromegaly
• Graves’ disease
• Type 1 diabetes
• Type 2 diabetes mellitus
• Obesity and overweight

The site’s 30 ongoing studies involve 23 investigators dedicated to endocrine research in the Bydgoszcz region.

Researchers are testing immune‑targeted therapies for conditions like active proliferative lupus nephritis and primary Sjögren’s syndrome. The aim is to achieve better disease control and reduce organ damage.

• Active proliferative lupus nephritis
• Primary Sjögren’s syndrome
• Psoriatic arthritis
• Autoimmune inflammatory disorders

A total of 30 clinical trials, supported by 23 investigators, underline the center’s commitment to advancing immunology.

The site evaluates therapies for chronic pain and joint degeneration, focusing on chronic low back pain and knee osteoarthritis. Studies seek to provide effective analgesic options and improve mobility.

• Chronic non‑specific low back pain
• Knee osteoarthritis
• Musculoskeletal inflammation

With 30 active trials and a team of 23 investigators, the facility addresses key musculoskeletal health challenges.

Clinical investigations target metabolic risk factors, testing agents that influence body weight, lipid profiles, and glucose regulation. The purpose is to lower cardiovascular risk and support weight management.

• Obesity
• Overweight
• Mixed dyslipidemia
• Metabolic syndrome components

The center’s 30 trials, conducted by 23 investigators, reflect a broad effort to combat metabolic disease in Poland.

Studies at the center assess symptomatic relief for upper‑respiratory infections, including acute rhinitis and rhinosinusitis that do not require antibiotics. The focus is on improving patient comfort and reducing disease duration.

• Acute rhinitis
• Rhinopharyngitis
• Rhinosinusitis (non‑antibiotic)

The research program includes 30 trials overseen by 23 clinicians, emphasizing practical treatment options for common respiratory ailments.

The department investigates therapies for inflammatory skin conditions such as psoriatic arthritis, aiming to reduce joint pain and skin lesions while preserving function.

• Psoriatic arthritis
• Skin connective‑tissue disorders

A portfolio of 30 clinical studies, driven by 23 investigators, supports advances in dermatologic and connective‑tissue disease treatment.

Trials explore novel approaches for major depressive disorder with insomnia and for alcohol addiction, seeking to enhance mood stabilization and support sustained sobriety.

• Major depressive disorder with insomnia
• Alcohol addiction

The center’s 30 active trials and 23 investigators reflect a dedicated effort to improve mental health outcomes in the region.